Regeneron (REGN) Tops Q3 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Leerink Partners Reiterated Outperform Following Regeneron's (REGN) 3Q Beat
November 5, 2015 8:07 AM ESTLeerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings report. REGN reported revenues and EPS of $1.14bn and $1.82, respectively, thereby beating consensus estimates of $1.79 and $1.64. REGN tightened its 2015 non-GAAP R&D guidance... More
Regeneron (REGN) Reports Strong Eylea Sales; Cowen Reiterates Market Perform
November 4, 2015 3:55 PM ESTCowen reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $575.00 (from $550.00), following the company's 3Q15 earnings report. Eylea sales of $734MM were well ahead of consensus of $683MM and 2015 guidance was increased again. Adoption... More
